JP2023539990A5 - - Google Patents
Info
- Publication number
- JP2023539990A5 JP2023539990A5 JP2023502702A JP2023502702A JP2023539990A5 JP 2023539990 A5 JP2023539990 A5 JP 2023539990A5 JP 2023502702 A JP2023502702 A JP 2023502702A JP 2023502702 A JP2023502702 A JP 2023502702A JP 2023539990 A5 JP2023539990 A5 JP 2023539990A5
- Authority
- JP
- Japan
- Prior art keywords
- dotaga
- euk
- sub
- lutetium
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051335P | 2020-07-13 | 2020-07-13 | |
| US63/051,335 | 2020-07-13 | ||
| US202163143664P | 2021-01-29 | 2021-01-29 | |
| US63/143,664 | 2021-01-29 | ||
| PCT/IB2021/000467 WO2022013610A2 (en) | 2020-07-13 | 2021-07-13 | Radiopharmaceutical and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539990A JP2023539990A (ja) | 2023-09-21 |
| JP2023539990A5 true JP2023539990A5 (enExample) | 2024-07-22 |
Family
ID=79171978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502702A Ceased JP2023539990A (ja) | 2020-07-13 | 2021-07-13 | 放射性薬剤および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11491246B2 (enExample) |
| EP (1) | EP4178628A4 (enExample) |
| JP (1) | JP2023539990A (enExample) |
| KR (1) | KR20240004205A (enExample) |
| AU (1) | AU2021309907A1 (enExample) |
| BR (1) | BR112023000763A2 (enExample) |
| CA (1) | CA3185565A1 (enExample) |
| IL (1) | IL299760A (enExample) |
| MX (1) | MX2023000623A (enExample) |
| TW (1) | TW202216205A (enExample) |
| WO (1) | WO2022013610A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023539990A (ja) | 2020-07-13 | 2023-09-21 | ポイント バイオファーマ インコーポレイテッド | 放射性薬剤および方法 |
| WO2023164769A1 (en) * | 2022-03-02 | 2023-09-07 | Point Biopharma, Inc. | Radiopharmaceutical and methods |
| CN114404618A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其用途 |
| CN114404619A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| WO2023215333A1 (en) * | 2022-05-02 | 2023-11-09 | Point Biopharma, Inc. | Radiopharmaceutical and methods |
| CN115015441B (zh) * | 2022-07-14 | 2023-08-18 | 原子高科股份有限公司 | 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法 |
| EP4558178A2 (en) * | 2022-07-18 | 2025-05-28 | Curium US LLC | Radiopharmaceutical compositions of copper for targeted molecular imaging |
| WO2024151320A2 (en) * | 2022-07-29 | 2024-07-18 | Curium Us Llc | [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof |
| EP4568985A1 (en) * | 2022-08-11 | 2025-06-18 | Advancell Isotopes Pty Limited | Radiopharmaceuticals |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| EP4630063A1 (en) | 2022-12-05 | 2025-10-15 | Novartis AG | Method of treating prostate cancer |
| TW202506204A (zh) * | 2023-04-14 | 2025-02-16 | 加拿大商融合製藥公司 | Psma靶向放射性藥物及dna損傷反應抑制劑之組合療法 |
| EP4743125A1 (en) | 2023-07-11 | 2026-05-20 | Novartis AG | PROSTATE CANCER TREATMENT METHOD |
| EP4746926A2 (en) | 2023-07-21 | 2026-05-27 | Novartis AG | Psma-targeting radioligand treatment regimen |
| AU2024317528A1 (en) * | 2023-07-31 | 2026-03-05 | Curium Us Llc | [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof |
| WO2025171492A1 (en) | 2024-02-14 | 2025-08-21 | Alpha-9 Oncology Inc. | Stable radiopharmaceutical compositions and uses thereof |
| WO2025235951A1 (en) * | 2024-05-09 | 2025-11-13 | Curium Us Llc | Radiopharmaceutical compositions for actinium in targeted radionuclide therapy |
| WO2026019453A1 (en) * | 2024-07-15 | 2026-01-22 | Curium Us Llc | [177lu]lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
| WO2026159621A1 (en) | 2025-01-23 | 2026-07-30 | Novartis Ag | Treatment regimen using psma-binding radioligands in combination with androgen receptor pathway inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2526760A1 (en) * | 2003-05-23 | 2005-01-06 | Epix Pharmaceuticals, Inc. | Optically pure and enriched isomers of chelating ligands and contrast agents |
| CN100418585C (zh) | 2003-07-24 | 2008-09-17 | 伯拉考成像股份公司 | 稳定的放射性药物组合物及制备方法 |
| WO2016149188A1 (en) | 2015-03-13 | 2016-09-22 | The Johns Hopkins University | 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| ES2743482T3 (es) | 2014-05-06 | 2020-02-19 | Univ Johns Hopkins | Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia |
| US10980901B2 (en) | 2016-12-15 | 2021-04-20 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of PMSA expressing cancers |
| US11478558B2 (en) | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
| US20200030466A1 (en) * | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
| AU2019345320B2 (en) | 2018-09-21 | 2025-12-11 | Endocyte, Inc. | Methods of treating cancer |
| WO2020064693A1 (en) | 2018-09-25 | 2020-04-02 | Advanced Accelerator Applications (Italy) Srl | Combination therapy |
| WO2020157177A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| JP2023539990A (ja) | 2020-07-13 | 2023-09-21 | ポイント バイオファーマ インコーポレイテッド | 放射性薬剤および方法 |
| US11129912B1 (en) * | 2020-07-13 | 2021-09-28 | POINT Biopharma Inc. | Radiopharmaceutical and methods |
| CN116528904A (zh) | 2020-08-27 | 2023-08-01 | 普罗博开发商业中心 | 放射性药物和方法 |
| WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
| WO2023097329A1 (en) | 2021-11-29 | 2023-06-01 | Point Biopharma, Inc. | Radiopharmaceutical treatment methods and use |
-
2021
- 2021-07-13 JP JP2023502702A patent/JP2023539990A/ja not_active Ceased
- 2021-07-13 TW TW110125666A patent/TW202216205A/zh unknown
- 2021-07-13 WO PCT/IB2021/000467 patent/WO2022013610A2/en not_active Ceased
- 2021-07-13 IL IL299760A patent/IL299760A/en unknown
- 2021-07-13 US US17/374,984 patent/US11491246B2/en active Active
- 2021-07-13 BR BR112023000763A patent/BR112023000763A2/pt not_active Application Discontinuation
- 2021-07-13 KR KR1020237004275A patent/KR20240004205A/ko not_active Withdrawn
- 2021-07-13 CA CA3185565A patent/CA3185565A1/en active Pending
- 2021-07-13 EP EP21841476.1A patent/EP4178628A4/en active Pending
- 2021-07-13 MX MX2023000623A patent/MX2023000623A/es unknown
- 2021-07-13 AU AU2021309907A patent/AU2021309907A1/en active Pending
- 2021-09-27 US US17/486,875 patent/US20220016274A1/en not_active Abandoned
-
2022
- 2022-09-22 US US17/934,450 patent/US20230302163A1/en active Pending
-
2023
- 2023-04-17 US US18/135,595 patent/US12558440B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0548114B1 (en) | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions | |
| JP5589130B1 (ja) | 結晶及び該結晶を含有してなる医薬製剤 | |
| RU2603963C2 (ru) | Кристалл, обладающий кристаллическими габитусами, и фармацевтическая композиция, полученная обработкой данного кристалла | |
| JPH0149127B2 (enExample) | ||
| JPS5815909A (ja) | 抗真菌外用剤 | |
| RU2009137779A (ru) | Композиции, содержащие (s)-2-амино-1-(4-хлорфенил)-1-[4-(1н-пиразол-4-ил)фенил]этанол, в качестве модуляторов протеинкиназ | |
| JPH0454646B2 (enExample) | ||
| US2803582A (en) | Local anesthetic composition | |
| JP2023540240A5 (enExample) | ||
| JPS6321648B2 (enExample) | ||
| JPH01500191A (ja) | 向骨性テクネチウム‐９９ｍ錯体 | |
| CN110845408A (zh) | 同位素富集的乐伐替尼 | |
| JP3072482B2 (ja) | 歯周炎治療用ミノサイクリン組成物 | |
| KR102295585B1 (ko) | 새로운 미네랄 주사제 조성물 | |
| JPS6333327A (ja) | 安定化されたフエニレフリン系液剤 | |
| WO2025016240A1 (zh) | 一种含环磺酮除草组合物的制备方法 | |
| JPS5933211A (ja) | 油性軟膏 | |
| US2388261A (en) | Riboflavin solution | |
| US4053570A (en) | Aluminum halohydrate | |
| CN109431996B (zh) | 一种含米诺地尔的外用剂组合物及其制备方法 | |
| EP0209511B1 (fr) | Chlorhydrates de chlorures de dérivés d'aminoalkyl-2 hydroxy-9 ellipticinium et compositions pharmaceutiques en contenant | |
| JP4630586B2 (ja) | 歯質再石灰化促進剤 | |
| US2744851A (en) | Cardiac glycosides for intramuscular injection | |
| JP4183750B2 (ja) | ファムシクロビル一水化物 | |
| JP2015027983A (ja) | 結晶及び該結晶を含有してなる医薬製剤 |